Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study
The atezolizumab plus bevacizumab is unlikely to be cost-effective compared with sorafenib for patients with unresectable HCC in the context of the USA and China. The implementation of significant reductions in drug prices may render the treatment economically viable.
Authors
- Yiling Ding
- Yamin Shu (ORCID: https://orcid.org/0000-0002-1532-8135)
- Lulu Liu (ORCID: https://orcid.org/0000-0001-9257-9512)
- Lei Wang (ORCID: https://orcid.org/0000-0001-6926-5523)
- Qilin Zhang (ORCID: https://orcid.org/0000-0002-4779-3875)
Institutions
- Union Hospital (HK)
- Army Medical University (CN)
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Wuhan Union Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-094804
- Citations
- 7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 9.25
Funders
- National Natural Science Foundation of China
- Chinese Pharmaceutical Association
- National Key Research and Development Program of China